Medical weight loss

Almost everyone reaches these medicines through one of four doors, and they differ more in clinical depth than in price.

• A primary care physician who already knows your history and can bill your insurance. Usually the cheapest route if you have coverage, and usually the slowest to get an appointment.
• A telehealth weight programme. Fast, cash-pay, subscription-shaped, and enormously variable in how much clinical review sits behind the prescription.
• A dedicated weight-management clinic. Typically the most monitoring, often the most expensive, sometimes in-network.
• A med spa or wellness clinic adding weight-loss injections to an aesthetics menu. The widest quality range of the four, and the one where the supervising-clinician question matters most.

None of these is disqualifying on its own. What matters is whether a licensed clinician reviews your history, whether anything is monitored after the first prescription, and whether the service is capable of telling you no.

Compounded copies of these medicines became widely available while the branded products were in shortage, under federal allowances tied specifically to shortage status. Those shortages have been declared resolved, which narrowed that permission substantially.

The status of compounded GLP-1 preparations is unsettled and we treat it as under review rather than stating it as settled fact. FDA's guidance to compounders sets out an "essentially a copy" test: a compounded product with the same active ingredient as a commercially available drug, in the same or an easily substitutable strength and by the same route, is generally treated as a copy unless a prescriber documents a significant difference for a specific patient. What that means for any particular preparation is a question for the pharmacy and the prescriber, not something a directory can answer for you.

A compounded preparation is not a generic. There is no generic semaglutide or tirzepatide in the United States. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed, which is the substantive difference behind the price difference.

We do not publish price ranges for these medicines, because any figure we could give you would be out of date and wrong for your situation. What we can tell you is which levers actually move it: whether you have coverage and whether your plan excludes weight-loss indications, the dose tier you end up on, whether the supply is branded or compounded, whether consultations and laboratory work sit inside the subscription or outside it, and what an introductory rate becomes in month three.

The most common expensive mistake is paying cash for a programme when the branded medication was covered under an in-network prescriber the whole time. Check your plan before you sign up for anything.

• Will a licensed clinician review my history, and can I find out who they are and where they are licensed?
• Is the medication branded or compounded — and if compounded, which pharmacy, and under what authority?
• What monitoring happens after I start, and is it included?
• If I have a side effect, who do I actually reach, and how fast?
• What is the total monthly cost after any introductory period?
• Is there a path where the answer is that this is not appropriate for me?

FDA publishes a list of telehealth warning signs for consumers, and it is worth reading before you hand over a card. Among them: a company claiming a compounded drug is the same as an FDA-approved one, prices that look too good to be true, medicine arriving that looks different from what was pictured, no screening or prescription by a licensed doctor, no licensed doctor reachable after the medicine arrives, and labels with spelling errors, wrong pharmacy addresses, or a pharmacy name that does not check out.

• Compounded semaglutideWhat semaglutide is, what compounding actually means, how the end of the shortage changed the rules, and the questions to ask any programme offering a compounded version.
• Compounding pharmacies and GLP-1 medicinesWhat 503A and 503B actually mean, how the two categories are regulated differently, and the specific things to establish about any pharmacy preparing a GLP-1 for you.
• Finding a weight-loss provider near youWhether being physically close to your prescriber matters for this category, when it genuinely does, and how to evaluate a local clinic against a remote one.
• Med spa weight-loss injectionsMed spas legitimately offer these medicines in many states. What differs is who supervises, what their licence permits, and what happens after hours — the questions that actually separate them.
• Telehealth weight-loss programmesHow remote weight-loss programmes are structured, what separates a clinical service from a subscription, and the questions that reveal which one you are looking at.
• Tirzepatide for weight lossWhat tirzepatide is, why engaging two incretin receptors makes it structurally different, which brand is licensed for weight management, and what drives access.
• Tirzepatide without insuranceWhat actually determines a cash price for tirzepatide — programme bundling, membership versus per-fill, manufacturer channels, and what changes month to month.
• Weight-loss injectionsWhat the phrase covers, how injectable weight-loss medicines differ from each other and from the things marketed alongside them, and what a legitimate prescribing process looks like.
• What weight-loss medication costsAn honest account of what drives GLP-1 and dual-agonist pricing — coverage exclusions, savings programmes, cash pharmacy routes, and what compounded pricing actually reflects.
• What is a GLP-1?GLP-1 is a hormone your gut already makes. This explains what the hormone does, what the drug class does differently, and why one term now covers medicines with quite different licences.
• What is tirzepatide?Tirzepatide is a dual incretin receptor agonist, not a second-generation semaglutide. What that means, which brands carry it, and what its compounded status is now.
• Where to get weight-loss injectionsThe four realistic routes to a prescription, what each one trades away, and how to tell which is right for your situation before you pay anyone.

• FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — retrieved 2026-08-06
• FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — retrieved 2026-08-06
• CMS — Contract Year 2026 Policy and Technical Changes to the Medicare Advantage and Part D Programs (CMS-4208-P) fact sheet — retrieved 2026-08-06